Ayala Pharmaceuticals (AYLA) Downgraded by Zacks Investment Research to Sell

Ayala Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Ayala Pharmaceuticals Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Ayala Pharmaceuticals traded down -$0.11 on Wednesday, reaching $10.10. 3745 shares of the stock traded hands, compared to its average volume of 39264. Shares of Ayala Pharmaceuticals were trading at $10.10 on Wednesday. The firm’s 50 day moving average is $12.21 and its 200 day moving average is $12.08.Ayala Pharmaceuticals has a 12 month low of $9.99 and a 12 month high of $28.68. While on yearly highs and lows, Ayala Pharmaceuticals’s today has traded high as $10.46 and has touched $9.99 on the downward trend. See More Analyst Rating at: RATING

Ayala Pharmaceuticals Earnings and What to expect: 

Ayala Pharmaceuticals last announced its earnings data on August 13th, 2021. The reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.10. The firm earned $0.76 million during the quarter, compared to the consensus estimate of $1.02 million. Ayala Pharmaceuticals has generated ($3.06) earnings per share over the last year (($2.81) diluted earnings per share). Earnings for Ayala Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($2.61) per share. Ayala Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 16th, 2021 based off prior year’s report dates.

Earnings for Ayala Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($2.61) per share. The P/E ratio of Ayala Pharmaceuticals is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Ayala Pharmaceuticals is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Ayala Pharmaceuticals has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Ayala Pharmaceuticals (AYLA) Moving Average Technical Analysis

5 day Moving Average is $10.12 And 5 day price change is -$0.89 (-8.14%)  with average volume for 5 day average is 13,300. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $11.03 and 20 day price change is -$3.98 (-28.29%) and average 20 day moving volume is 47,370. 50 day moving average is $12.21  and 50 day price change is -$3.50 ( -25.74%)  and with average volume for 50 days is : 33,182. 200 day moving average is $12.08  and 200 day price change is -$1.89 (-15.76%)  and with average volume for 200 days is : 29,122.

Other owners latest trading in Ayala Pharmaceuticals :

  • On 8/25/2021 shares held by Marshall Wace North America L.P. were 49,266 which equates to market value of $0.50M and appx 0.00% owners of Ayala Pharmaceuticals
  • On 8/17/2021 shares held by Citadel Advisors LLC were 10,457 which equates to market value of $0.11M and appx 0.00% owners of Ayala Pharmaceuticals
  • On 8/17/2021 shares held by Bridgeway Capital Management LLC were 31,962 which equates to market value of $0.33M and appx 0.00% owners of Ayala Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 15.50% for Ayala Pharmaceuticals

See More Analyst Rating at: RATING